Drug Makers, Benefit Managers Hit With Class Suit Alleging Insulin Pricing Scheme

(March 22, 2017, 11:58 AM EDT) -- NEWARK, N.J. — Three drug makers and the three largest pharmacy benefit managers have engaged in a pricing scheme to drive up the cost of diabetes insulin — by more than 150 percent in the last five years — in violation of the Racketeer Influenced and Corrupt Organizations Act, the Employee Retirement Income Security Act of 1974, the Sherman Act and numerous state laws, four consumers and Type 1 Diabetes Defense Foundation allege in a March 17 class complaint filed in the U.S. District Court for the District of New Jersey (Julia Boss, et al. v. CVS Health Corporation, et al., No. 17-1823, D. N.J.)....